Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own48.07% Shs Outstand37.53M Perf Week-4.41%
Market Cap439.48M Forward P/E- EPS next Y- Insider Trans5.25% Shs Float19.49M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh-3.17 P/B- EPS next Y- ROA- Short Interest- Perf Year-
Cash/sh7.81 P/C1.50 EPS next 5Y- ROE- 52W Range9.74 - 12.74 Perf YTD13.58%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-8.08% Beta-
Dividend TTM- Quick Ratio4.36 Sales past 5Y6978.19% Gross Margin- 52W Low20.23% ATR (14)1.14
Dividend Ex-Date- Current Ratio4.36 EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility7.09% -
Employees200 Debt/Eq0.21 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.20 EPS Q/Q- Payout- Rel Volume0.25 Prev Close11.30
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume756.12K Price11.71
SMA200.74% SMA500.74% SMA2000.74% Trades Volume192,372 Change3.63%
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerFeb 13Buy15.00800,00012,000,0001,739,175Feb 15 08:38 PM
Novo Holdings A/S10% OwnerFeb 09Buy10.25100,0001,025,000100,000Feb 15 08:38 PM